How have CYCN shares performed in 2024?

Cyclerion Therapeutics' stock was trading at $3.35 at the beginning of the year. Since then, CYCN shares have increased by 4.5% and is now trading at $3.50. View the best growth stocks for 2024 here .

Are investors shorting Cyclerion Therapeutics?

Cyclerion Therapeutics saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 22,100 shares, a decrease of 6.0% from the March 15th total of 23,500 shares. Based on an average daily volume of 3,000 shares, the short-interest ratio is presently 7.4 days. Currently, 1.2% of the shares of the stock are sold short. View Cyclerion Therapeutics' Short Interest .

When is Cyclerion Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CYCN earnings forecast .

How were Cyclerion Therapeutics' earnings last quarter?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) announced its quarterly earnings results on Tuesday, November, 9th. The company reported ($5.20) earnings per share for the quarter, topping analysts' consensus estimates of ($7.00) by $1.80. The company earned $0.35 million during the quarter, compared to the consensus estimate of $3 million.

When did Cyclerion Therapeutics' stock split?

Cyclerion Therapeutics shares reverse split before market open on Tuesday, May 16th 2023. The 1-20 reverse split was announced on Tuesday, May 16th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 16th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Cyclerion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclerion Therapeutics investors own include Fulcrum Therapeutics (FULC) , Ovid Therapeutics (OVID) , Spectrum Pharmaceuticals (SPPI) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Xeris Biopharma (XERS) , Abeona Therapeutics (ABEO) , ACADIA Pharmaceuticals (ACAD) , Aimmune Therapeutics (AIMT) and Celldex Therapeutics (CLDX) .

How do I buy shares of Cyclerion Therapeutics?

Shares of CYCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CYCN

Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free CYCN Stock Alerts

$3.50

+0.28 (+8.70%)

(As of 04/19/2024 ET)

Compare

Today's Range: $3.15
▼
$3.50
50-Day Range: $2.80
▼
$3.60
52-Week Range: $1.75
▼
$6.80

Volume: 3,292 shs
Average Volume: 3,242 shs
Market Capitalization: $9.49 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Cyclerion Therapeutics alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Cyclerion Therapeutics Stock (NASDAQ:CYCN)

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018, a CNS-targeted sGC stimulator that is in preclinical trial for the treatment of neuropsychiatric diseases and disorders. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

CYCN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CYCN Stock News Headlines

April 18, 2024 | americanbankingnews.com

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Down 6.0% in March

April 5, 2024 | investorplace.com

CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 6, 2024 | investing.com

Cyclerion Therapeutics Inc (CYCN)

February 29, 2024 | uk.finance.yahoo.com

Cyclerion Therapeutics, Inc. (CYCN)

February 23, 2024 | benzinga.com

Cyclerion Therapeutics Stock (NASDAQ:CYCN) Dividends: History, Yield and Dates

December 4, 2023 | msn.com

Cyclerion Therapeutics appoints Graul as President

November 30, 2023 | finance.yahoo.com

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

November 28, 2023 | finance.yahoo.com

Cyclerion Therapeutics' Market Cap Drops To US$5.0m Leaving Insiders With Losses

July 31, 2023 | finance.yahoo.com

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

June 30, 2023 | ca.finance.yahoo.com

CYCN - Cyclerion Therapeutics, Inc.

June 2, 2023 | finanznachrichten.de

Cyclerion Therapeutics, Inc.: Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement

June 1, 2023 | msn.com

Cyclerion Therapeutics in compliance with Nasdaq minimum bid price rule

May 16, 2023 | finanznachrichten.de

Cyclerion Therapeutics, Inc.: Cyclerion Announces Reverse Stock Split

May 15, 2023 | msn.com

Cyclerion announces 1 for 20 reverse stock split

May 12, 2023 | finance.yahoo.com

Cyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New Investors

May 12, 2023 | finanznachrichten.de

Cyclerion Therapeutics, Inc.: Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

May 12, 2023 | msn.com

Cyclerion Therapeutics down 6% on spin off agreement

May 11, 2023 | finance.yahoo.com

Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

May 11, 2023 | finance.yahoo.com

Cyclerion Announces Definitive Agreement for Zagociguat and CY3018

April 3, 2023 | finanznachrichten.de

Cyclerion Therapeutics, Inc.: Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement

March 27, 2023 | marketwatch.com

Cyclerion Gets FDA Orphan Designation for Zagociguat in Mitochondrial Diseases >CYCN

March 23, 2023 | finanznachrichten.de

Cyclerion Therapeutics, Inc.: Cyclerion Reports Corporate Update and Full Year 2022 Financial Results

March 22, 2023 | finance.yahoo.com

Cyclerion Reports Corporate Update and Full Year 2022 Financial Results

November 23, 2022 | msn.com

Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday

November 22, 2022 | marketwatch.com

Cyclerion Shares Rise After Spurned Bid for Assets

See More Headlines

Receive CYCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CYCN
CUSIP: N/A
CIK: 1755237
Web: www.cyclerion.com
Phone: (857) 327-8778
Fax: N/A
Employees: 1
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($5.51)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-5,260,000.00
Net Margins: N/A
Pretax Margin: -742.76%
Return on Equity: -111.79%
Return on Assets: -74.10%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.85
Quick Ratio: 3.85

Sales & Book Value

Annual Sales: $1.62 million
Price / Sales: 5.85
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.62 per share
Price / Book: 0.76

Miscellaneous

Outstanding Shares: 2,710,000
Free Float: 2,355,000
Market Cap: $9.49 million
Optionable: No Data
Beta: 1.84

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Regina Graul Ph.D.
President
Ms. Rhonda M. Chicko (Age 57)
Chief Financial Officer
Dr. Todd Milne Ph.D.
Senior Vice President of External Innovation
Ms. Jessica Rennekamp
Associate Director of Corporate Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CYCN Stock Analysis - Frequently Asked Questions

How have CYCN shares performed in 2024?: Cyclerion Therapeutics' stock was trading at $3.35 at the beginning of the year. Since then, CYCN shares have increased by 4.5% and is now trading at $3.50.
View the best growth stocks for 2024 here.
Are investors shorting Cyclerion Therapeutics?: Cyclerion Therapeutics saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 22,100 shares, a decrease of 6.0% from the March 15th total of 23,500 shares. Based on an average daily volume of 3,000 shares, the short-interest ratio is presently 7.4 days. Currently, 1.2% of the shares of the stock are sold short.
View Cyclerion Therapeutics' Short Interest.
When is Cyclerion Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CYCN earnings forecast.
How were Cyclerion Therapeutics' earnings last quarter?: Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) announced its quarterly earnings results on Tuesday, November, 9th. The company reported ($5.20) earnings per share for the quarter, topping analysts' consensus estimates of ($7.00) by $1.80. The company earned $0.35 million during the quarter, compared to the consensus estimate of $3 million.

When did Cyclerion Therapeutics' stock split?: Cyclerion Therapeutics shares reverse split before market open on Tuesday, May 16th 2023. The 1-20 reverse split was announced on Tuesday, May 16th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 16th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Cyclerion Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclerion Therapeutics investors own include Fulcrum Therapeutics (FULC), Ovid Therapeutics (OVID), Spectrum Pharmaceuticals (SPPI), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Xeris Biopharma (XERS), Abeona Therapeutics (ABEO), ACADIA Pharmaceuticals (ACAD), Aimmune Therapeutics (AIMT) and Celldex Therapeutics (CLDX).
How do I buy shares of Cyclerion Therapeutics?: Shares of CYCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CYCN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis

About Cyclerion Therapeutics Stock (NASDAQ:CYCN)

CYCN Stock Price History

CYCN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CYCN Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info